DATA INDICATE THAT WHOLE-INACTIVATED HIV-1 IMMUNOGEN INDUCES HIV-SPECIFIC IMMUNE RESPONSES IN HIV-IN
The Immune Response Corporation announced today that the final results from
a Phase II clinical study indicate that the Company's whole-inactivated HIV-1
immunogen induces HIV-specific immune responses in HIV-infected, antiretroviral
drug-naive patients. Specifically, this original formulation product showed
potential to stimulate key immunologic parameters and to stabilize the loss
of CD4+ cells, which could help prolong the time before these patients need
to initiate antiretroviral therapy.